CD19 and myeloid neoplasm: In the context of cellular therapy, the US Food and Drug Administration (FDA) approval of two CD19-directed CAR T cells products, KymriahTM and YescartaTM, revolutionized the field of immunotherapy and ignited our enthusiasm for translating this promising technology to the treatment of myeloid malignancies.